Search

Your search keyword '"Celsa, Ciro"' showing total 340 results
Start Over Author "Celsa, Ciro"
340 results on '"Celsa, Ciro"'

52. The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints

Author

Giuffrida, Paolo, primary, Celsa, Ciro, additional, Antonucci, Michela, additional, Peri, Marta, additional, Grassini, Maria Vittoria, additional, Rancatore, Gabriele, additional, Giacchetto, Carmelo Marco, additional, Cannella, Roberto, additional, Incorvaia, Lorena, additional, Corsini, Lidia Rita, additional, Morana, Piera, additional, La Mantia, Claudia, additional, Badalamenti, Giuseppe, additional, Brancatelli, Giuseppe, additional, Cammà, Calogero, additional, and Cabibbo, Giuseppe, additional

Published
2022
Full Text
View/download PDF

53. Reply

Author

Vizzutti, Francesco, primary, Celsa, Ciro, additional, Battaglia, Salvatore, additional, Miraglia, Roberto, additional, Enea, Marco, additional, Marra, Fabio, additional, Caporali, Cristian, additional, Cammà, Calogero, additional, and Schepis, Filippo, additional

Published
2022
Full Text
View/download PDF

54. Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis

Author

Pennisi, Grazia, primary, Celsa, Ciro, additional, Enea, Marco, additional, Vaccaro, Marco, additional, Di Marco, Vito, additional, Ciccioli, Carlo, additional, Infantino, Giuseppe, additional, La Mantia, Claudia, additional, Parisi, Stefanie, additional, Vernuccio, Federica, additional, Craxì, Antonio, additional, Cammà, Calogero, additional, and Petta, Salvatore, additional

Published
2022
Full Text
View/download PDF

56. Endothelial angiopoietin-2 overexpression in explanted livers identifies subjects at higher risk of recurrence of hepatocellular carcinoma after liver transplantation

Author

Lasagni, Simone, primary, Leonardi, Filippo, additional, Pivetti, Alessandra, additional, Di Marco, Lorenza, additional, Ravaioli, Federico, additional, Serenari, Matteo, additional, Gitto, Stefano, additional, Critelli, Rosina Maria, additional, Milosa, Fabiola, additional, Romanzi, Adriana, additional, Mancarella, Serena, additional, Dituri, Francesco, additional, Riefolo, Mattia, additional, Catellani, Barbara, additional, Magistri, Paolo, additional, Romagnoli, Dante, additional, Celsa, Ciro, additional, Enea, Marco, additional, de Maria, Nicola, additional, Schepis, Filippo, additional, Colecchia, Antonio, additional, Cammà, Calogero, additional, Cescon, Matteo, additional, d’Errico, Antonietta, additional, di Benedetto, Fabrizio, additional, Giannelli, Gianluigi, additional, Martinez-Chantar, Maria Luz, additional, and Villa, Erica, additional

Published
2022
Full Text
View/download PDF

57. Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma

Author

Giannini, Edoardo G., primary, Pieri, Giulia, additional, Labanca, Sara, additional, Plaz Torres, Maria Corina, additional, Gasbarrini, Antonio, additional, Biasini, Elisabetta, additional, Campani, Claudia, additional, Cazzagon, Nora, additional, Foschi, Francesco Giuseppe, additional, Mega, Andrea, additional, Masotto, Alberto, additional, Raimondo, Giovanni, additional, Rapaccini, Gian Ludovico, additional, Sacco, Rodolfo, additional, Caturelli, Eugenio, additional, Guarino, Maria, additional, Tovoli, Francesco, additional, Vidili, Gianpaolo, additional, Brunetto, Maurizia Rossana, additional, Nardone, Gerardo, additional, Svegliati-Baroni, Gianluca, additional, Magalotti, Donatella, additional, Azzaroli, Francesco, additional, Cabibbo, Giuseppe, additional, Di Marco, Maria, additional, Sangiovanni, Angelo, additional, Trevisani, Franco, additional, Biselli, Maurizio, additional, Caraceni, Paolo, additional, Gramenzi, Annagiulia, additional, Benevento, Francesca, additional, Granito, Alessandro, additional, Muratori, Luca, additional, Piscaglia, Fabio, additional, Bertellini, Federica, additional, Farinati, Fabio, additional, Palano, Giorgio, additional, Pelizzaro, Filippo, additional, Penzo, Barbara, additional, Pinto, Elisa, additional, Allegrini, Gloria, additional, Cammà, Calogero, additional, Celsa, Ciro, additional, Giuffrida, Paolo, additional, Stornello, Caterina, additional, Grova, Mauro, additional, Giacchetto, Carmelo Marco, additional, Rancatore, Gabriele, additional, Grassini, Maria Vittoria, additional, Adotti, Valentina, additional, Gitto, Stefano, additional, Marra, Fabio, additional, Rosi, Martina, additional, Bevilacqua, Vittoria, additional, Borghi, Alberto, additional, Gardini, Andrea Casadei, additional, Conti, Fabio, additional, Napoli, Lucia, additional, Domenicali, Marco, additional, Migliano, Maria Teresa, additional, de Matthaeis, Nicoletta, additional, Ponziani, Francesca Romana, additional, Olivani, Andrea, additional, Missale, Gabriele, additional, Cossiga, Valentina, additional, Capasso, Mario, additional, Morisco, Filomena, additional, Cela, Ester Marina, additional, Facciorusso, Antonio, additional, Lauria, Valentina, additional, Ghittoni, Giorgia, additional, Pelecca, Giorgio, additional, Chegai, Fabrizio, additional, Coratella, Fabio, additional, Ortenzi, Mariano, additional, Dell'Isola, Serena, additional, Franzè, Maria Stella, additional, Saitta, Carlo, additional, Sauchella, Assunta, additional, Dajti, Elton, additional, Ravaioli, Federico, additional, Oliveri, Filippo, additional, Ricco, Gabriele, additional, Romagnoli, Veronica, additional, Inno, Alessandro, additional, Marchetti, Fabiana, additional, Coccoli, Pietro, additional, Malerba, Antonio, additional, Cappelli, Alberta, additional, Golfieri, Rita, additional, Mosconi, Cristina, additional, and Renzulli, Matteo, additional

Published
2022
Full Text
View/download PDF

59. RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices

Author

Calvaruso, Vincenza, Celsa, Ciro, D'Ambrosio, Roberta, Simone, Fabio, Petta, Salvatore, Cacciola, Irene, Enea, Marco, Battaglia, Salvatore, Pandolfo, Alessandra, Licata, Massimo, Degasperi, Elisabetta, Cabibbo, Giuseppe, Di Marco, Lorenza, Pennisi, Grazia, Borghi, Marta, Di Martino, Vincenzo, Filomia, Roberto, Abdel-Hadi, Yasmin, Crapanzano, Luciano, Raimondo, Giovanni, Lampertico, Pietro, Craxì, Antonio, Cammà, Calogero, Di Marco, Vito, Calvaruso, Vincenza, Celsa, Ciro, D'Ambrosio, Roberta, Simone, Fabio, Petta, Salvatore, Cacciola, Irene, Enea, Marco, Battaglia, Salvatore, Pandolfo, Alessandra, Licata, Massimo, Degasperi, Elisabetta, Cabibbo, Giuseppe, Di Marco, Lorenza, Pennisi, Grazia, Borghi, Marta, Di Martino, Vincenzo, Filomia, Roberto, Abdel-Hadi, Yasmin, Crapanzano, Luciano, Raimondo, Giovanni, Lampertico, Pietro, Craxì, Antonio, Cammà, Calogero, and Di Marco, Vito

Subjects
Antiviral Agent, Male, Liver Cirrhosis, Hepatology, Platelet Count, Liver Cirrhosi, Gastroenterology, Hepacivirus, Hepatitis C, Chronic, Esophageal and Gastric Varices, Antiviral Agents, Elasticity Imaging Techniques, Esophageal and Gastric Varice, Humans, Female, Serum Albumin, Human, Aged
Abstract

Noninvasive criteria to predict the progression of low-risk esophageal varices (EV) in patients with compensated hepatitis C virus (HCV) cirrhosis after sustained virological response (SVR) by direct-acting antivirals (DAAs) are lacking. Our aim was to assess the diagnostic performance of Rete Sicilia Selezione Terapia-HCV (RESIST-HCV) criteria for EV progression compared with elastography-based criteria (Baveno VI, Expanded Baveno VI, and Baveno VII-HCV criteria).All consecutive patients observed at 3 referral centers with compensated HCV cirrhosis with or without F1 EV who achieved sustained virological response by DAAs were classified at last esophagogastroduodenoscopy (EGDS) as RESIST-HCV low risk (i.e., low probability of high-risk varices [HRV]) if platelets were120 × 10 9 /L and serum albumin3.6 g/dL or RESIST-HCV high risk (i.e., high probability of HRV) if platelets were120 × 10 9 /L or serum albumin3.6 g/dL. The primary outcome was the progression to HRV. The area under the receiver operating characteristic curve and decision curve analysis of noninvasive criteria were calculated.The cohort consisted of 353 patients in Child-Pugh class A (mean age 67.2 years, 53.8% males). During a mean follow-up of 44.2 months, 34 patients (9.6%, 95% CI 6.7%-13.5%) developed HRV. At the last EGDS, 178 patients (50.4%) were RESIST-low risk, and 175 (49.6%) were RESIST-high risk. RESIST-HCV criteria showed the highest area under the receiver operating characteristic curve (0.70, 95% confidence interval 0.65-0.75), correctly sparing the highest number of EGDS (54.3%), with the lowest false-positive rate (45.7%), compared with elastography-based criteria. Decision curve analysis showed that RESIST-HCV had higher clinical utility than elastography-based criteria.Biochemical-based RESIST-HCV criteria are useful to easily predict HRV development after HCV eradication by DAAs in patients with compensated cirrhosis and low-risk EV.

Published
2022

60. Hepatectomy Versus Sorafenib in Advanced Non-Metastatic Hepatocellular Carcinoma: A Real-Life Multicentric Weighted Comparison

Author

Famularo, Simone, Donadon, Matteo, Cipriani, Federica, Giuliante, Felice, Ferri, Silvia, Celsa, Ciro, Ferrero, Alessandro, Foschi, Francesco Giuseppe, Baiocchi, Gian Luca, Biasini, Elisabetta, Campani, Claudia, Valle, Raffaele Dalla, Pellizzaro, Filippo, Baroni, Gianluca Svegliati, Raimondo, Giovanni, Mega, Andrea, Chiarelli, Marco, Maestri, Marcello, Gasbarrini, Antonio, Jovine, Elio, Grazi, Gian Luca, Rapaccini, Gian Ludovico, Ruzzenente, Andrea, Morisco, Filomena, Sacco, Rodolfo, Memeo, Riccardo, Crespi, Michele, Antonucci, Adelmo, Bernasconi, Davide P, Romano, Fabrizio, Griseri, Guido, Aldrighetti, Luca, Torzilli, Guido, Trevisani, Franco, Famularo, S, Donadon, M, Cipriani, F, Giuliante, F, Ferri, S, Celsa, C, Ferrero, A, Foschi, F, Baiocchi, G, Biasini, E, Campani, C, Valle, R, Pellizzaro, F, Baroni, G, Raimondo, G, Mega, A, Chiarelli, M, Maestri, M, Gasbarrini, A, Jovine, E, Grazi, G, Rapaccini, G, Ruzzenente, A, Morisco, F, Sacco, R, Memeo, R, Crespi, M, Antonucci, A, Bernasconi, D, Romano, F, Griseri, G, Aldrighetti, L, Torzilli, G, Trevisani, F, Famularo, Simone, Donadon, Matteo, Cipriani, Federica, Giuliante, Felice, Ferri, Silvia, Celsa, Ciro, Ferrero, Alessandro, Foschi, Francesco Giuseppe, Baiocchi, Gian Luca, Biasini, Elisabetta, Campani, Claudia, Valle, Raffaele Dalla, Pelizzaro, Filippo, Baroni, Gianluca Svegliati, Raimondo, Giovanni, Mega, Andrea, Chiarelli, Marco, Maestri, Marcello, Gasbarrini, Antonio, Jovine, Elio, Grazi, Gian Luca, Rapaccini, Gian Ludovico, Ruzzenente, Andrea, Morisco, Filomena, Sacco, Rodolfo, Memeo, Riccardo, Crespi, Michele, Antonucci, Adelmo, Bernasconi, Davide P, Romano, Fabrizio, Griseri, Guido, Aldrighetti, Luca, Torzilli, Guido, Trevisani, Franco, and Pellizzaro, Filippo

Subjects
Niacinamide, Carcinoma, Hepatocellular, Hepatocellular carcinoma, hepatocellular carcinoma, surgery, sorafenib, bclc, Phenylurea Compounds, Carcinoma, Settore MED/09 - MEDICINA INTERNA, Liver Neoplasms, advanced HCC, Hepatocellular, Antineoplastic Agents, systemic therapies, Sorafenib, BCLC C, NO, Treatment Outcome, macrovascular invasion, Humans, Hepatectomy, Surgery, Neoplasm Staging, Retrospective Studies, Liver surgery
Abstract

Objective: The aim of the study was to compare SURG vs SOR regarding the OS and progression-free survival (PFS) in a real-world clinical scenario. Background data: The treatment for advanced nonmetastatic HCC belonging to the Barcelona Clinic Liver Cancer stage C (BCLC C) is still controversial. Methods: BCLC C patients without extrahepatic spread and tumoral invasion of the main portal trunk were considered. Surgical patients were obtained from the HE.RC.O.LE.S. Register, whereas sorafenib patients were obtained from the ITA.LI.CA register The inverse probability weighting (IPW) method was adopted to balance the confounders between the 2 groups. Results: Between 2008 and 2019, 478 patients were enrolled: 303 in SURG and 175 in SOR group. Eastern Cooperative Oncological Group Performance Status (ECOG-PS), presence of cirrhosis, steatosis, Child-Pugh grade, hepatitis B virus and hepatitis C virus, alcohol intake, collateral veins, bilobar disease, localization of the tumor thrombus, number of nodules, alpha-fetoprotein, age, and Charlson Comorbidity index were weighted by IPW to create two balanced pseudo-populations: SURG = 374 and SOR = 263. After IPW, 1-3-5 years OS was 83.6%, 68.1%, 55.9% for SURG, and 42.3%, 17.8%, 12.8% for SOR (P < 0.001). Similar trends were observed after subgrouping patients by ECOG-PS = 0 and ECOG-PS >0, and by the intrahepatic location of portal vein invasion. At Cox regression, sorafenib treatment (hazard ratio 4.436; 95% confidence interval 3.19-6.15; P < 0.001) and Charlson Index (hazard ratio 1.162; 95% confidence interval 1.06-1.27; P = 0.010) were the only independent predictors of mortality. PFS at 1-3-5 years were 65.9%, 40.3%, 24.3% for SURG and 21.6%, 3.5%, 2.9% for SOR (P = 0.007). Conclusions: In BCLC C patients without extrahepatic spread but with intrahepatic portal invasion, liver resection, if feasible, was followed by better OS and PFS compared with sorafenib.

Published
2022

61. Validation of the easy‐to‐use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib

Author

Rimini, Margherita, primary, Kang, Wonseok, additional, Burgio, Valentina, additional, Persano, Mara, additional, Aoki, Tamoko, additional, Shimose, Shigeo, additional, Tada, Toshifumi, additional, Kumada, Takashi, additional, Sho, Takuya, additional, Lai, Eleonora, additional, Celsa, Ciro, additional, Campani, Claudia, additional, Tonnini, Matteo, additional, Tamburini, Emiliano, additional, Hiraoka, Atsushi, additional, Takaguchi, Koichi, additional, Nishida, Naoshi, additional, Iwamoto, Hideki, additional, Itobayashi, Ei, additional, Tsuji, Kunihiko, additional, Sakamoto, Naoya, additional, Ishikawa, Toru, additional, Toyoda, Hidenori, additional, Kudo, Masatoshi, additional, Kawaguchi, Takumi, additional, Hatanaka, Takeshi, additional, Nouso, Kazugiro, additional, Suda, Goki, additional, Cabibbo, Giuseppe, additional, Marra, Fabio, additional, Della Corte, Angelo, additional, Ratti, Francesca, additional, Pedica, Federica, additional, De Cobelli, Francesco, additional, Aldrighetti, Luca, additional, Scartozzi, Mario, additional, Cascinu, Stefano, additional, and Casadei‐Gardini, Andrea, additional

Published
2022
Full Text
View/download PDF

62. Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction model

Author

Vizzutti, Francesco, primary, Celsa, Ciro, additional, Calvaruso, Vincenza, additional, Enea, Marco, additional, Battaglia, Salvatore, additional, Turco, Laura, additional, Senzolo, Marco, additional, Nardelli, Silvia, additional, Miraglia, Roberto, additional, Roccarina, Davide, additional, Campani, Claudia, additional, Saltini, Dario, additional, Caporali, Cristian, additional, Indulti, Federica, additional, Gitto, Stefano, additional, Zanetto, Alberto, additional, Di Maria, Gabriele, additional, Bianchini, Marcello, additional, Pecchini, Maddalena, additional, Aspite, Silvia, additional, Di Bonaventura, Chiara, additional, Citone, Michele, additional, Guasconi, Tomas, additional, Di Benedetto, Fabrizio, additional, Arena, Umberto, additional, Fanelli, Fabrizio, additional, Maruzzelli, Luigi, additional, Riggio, Oliviero, additional, Burra, Patrizia, additional, Colecchia, Antonio, additional, Villa, Erica, additional, Marra, Fabio, additional, Cammà, Calogero, additional, and Schepis, Filippo, additional

Published
2022
Full Text
View/download PDF

63. Ruling out varices needing treatment with a non-invasive score in patients with compensated HBV cirrhosis

Author

Maria Rizzo, Giacomo Emanuele, primary, Graceffa, Pietro, additional, Bronte, Fabrizio, additional, Falco, Giuseppe, additional, Rancatore, Gabriele, additional, Celsa, Ciro, additional, Reina, Giada, additional, Simone, Fabio, additional, Peralta, Sergio, additional, Craxi, Antonio, additional, Di Marco, Vito, additional, and Calvaruso, Vincenza, additional

Published
2022
Full Text
View/download PDF

64. Efficacy and safety of Atezolizumab plus Bevacizumab-based sequential treatment for unresectable hepatocellular carcinoma: a simulation model

Author

Celsa, Ciro, primary, Cabibbo, Giuseppe, additional, Battaglia, Salvatore, additional, Giuffrida, Paolo, additional, Maria Rizzo, Giacomo Emanuele, additional, Grova, Mauro, additional, Giacchetto, Marco, additional, Rancatore, Gabriele, additional, Stornello, Caterina, additional, Grassini, Maria Vittoria, additional, Badalamenti, Giuseppe, additional, Enea, Marco, additional, Craxi, Antonio, additional, Di Marco, Vito, additional, and Camma, Calogero, additional

Published
2022
Full Text
View/download PDF

65. AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD

Author

Pennisi, Grazia, primary, Enea, Marco, additional, Pandolfo, Alessandra, additional, Celsa, Ciro, additional, Antonucci, Michela, additional, Ciccioli, Carlo, additional, Infantino, Giuseppe, additional, La Mantia, Claudia, additional, Parisi, Stefanie, additional, Tulone, Adele, additional, Di Marco, Vito, additional, Craxì, Antonio, additional, Cammà, Calogero, additional, and Petta, Salvatore, additional

Published
2022
Full Text
View/download PDF

66. Spontaneous and drug-induced histological changes in non-alcoholic steatohepatitis: an assessment by meta-analysis of trials

Author

Pennisi, Grazia, primary, Celsa, Ciro, additional, Enea, Marco, additional, Vaccaro, Marco, additional, Di Marco, Vito, additional, Ciccioli, Carlo, additional, Infantino, Giuseppe, additional, Parisi, Stefanie, additional, La Mantia, Claudia, additional, Craxi, Antonio, additional, Camma, Calogero, additional, and Petta, Salvatore, additional

Published
2022
Full Text
View/download PDF

67. Diagnostic performance of AGILE 3+ score for identification of advanced fibrosis and prediction of liver-related events in patients with non-alcoholic fatty liver disease

Author

Pennisi, Grazia, primary, Celsa, Ciro, additional, Enea, Marco, additional, Pandolfo, Alessandra, additional, Antonucci, Michela, additional, Ciccioli, Carlo, additional, Infantino, Giuseppe, additional, La Mantia, Claudia, additional, Parisi, Stefanie, additional, Tulone, Adele, additional, Di Marco, Vito, additional, Craxi, Antonio, additional, Camma, Calogero, additional, and Petta, Salvatore, additional

Published
2022
Full Text
View/download PDF

68. OS-078-YI Hepatic decompensation as an aetiology-dependent determinant of mortality in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab

Author

Celsa, Ciro, Cabibbo, Giuseppe, Fulgenzi, Claudia, Scheiner, Bernhard, Battaglia, Salvatore, D'Alessio, Antonio, Manfredi, Giulia, Stefanini, Bernardo, Nishida, Naoshi, Galle, Peter R., Schulze, Kornelius, Wege, Henning, Ciccia, Roberta, Hsu, Wei-Fan, Vivaldi, Caterina, Wietharn, Brooke, Lin, Po-Ting, Pirozzi, Angelo, Pressiani, Tiziana, Dalbeni, Andrea, Natola, Leonardo Antonio, Auriemma, Alessandra, Rigamonti, Cristina, Burlone, Michela Emma, Parisi, Alessandro, Huang, Yi-Hsiang, Lee, Pei-Chang, Ang, Celina, Marron, Thomas, Pinter, Matthias, Cheon, Jaekyung, Chon, Hong Jae, Phen, Samuel, Singal, Amit, Gampa, Anuhya, Pillai, Anjana, Thimme, Robert, Vogel, Arndt, Soror, Noha, Ulahannan, Susanna V., Sharma, Rohini, Sacerdoti, David, Pirisi, Mario, Rimassa, Lorenza, Lin, Chun-yen, Saeed, Anwaar, Röhlen, Natascha, Masi, Gianluca, Schoenlein, Martin, von Felden, Johann, Kudo, Masatoshi, Cortellini, Alessio, Camma, Calogero, and Pinato, David J.

Published
2024
Full Text
View/download PDF

69. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis

Author

Universidad de Sevilla. Departamento de Medicina, Sapena, Victor, Enea, Marco, Torres, Ferran, Celsa, Ciro, Ríos, José J., Rizzo, Giacomo Emanuele Maria, Nahon, Pierre, Merchante Gutiérrez, Nicolás, Reig, Maria, Universidad de Sevilla. Departamento de Medicina, Sapena, Victor, Enea, Marco, Torres, Ferran, Celsa, Ciro, Ríos, José J., Rizzo, Giacomo Emanuele Maria, Nahon, Pierre, Merchante Gutiérrez, Nicolás, and Reig, Maria

Abstract

Objective The benefit of direct-acting antivirals (DAAs) against HCV following successful treatment of hepatocellular carcinoma (HCC) remains controversial. This meta-analysis of individual patient data assessed HCC recurrence risk following DAA administration. Design We pooled the data of 977 consecutive patients from 21 studies of HCV-related cirrhosis and HCC, who achieved complete radiological response after surgical/locoregional treatments and received DAAs (DAA group). Recurrence or death risk was expressed as HCC recurrence or death per 100 person-years (100PY). Propensity score-matched patients from the ITA.LI.CA. cohort (n=328) served as DAA-unexposed controls (no-DAA group). Risk factors for HCC recurrence were identified using random-effects Poisson. Results Recurrence rate and death risk per 100PY in DAA-treated patients were 20 (95% CI 13.9 to 29.8, I2=74.6%) and 5.7 (2.5 to 15.3, I2=54.3), respectively. Predictive factors for recurrence were alpha-fetoprotein logarithm (relative risk (RR)=1.11, 95% CI 1.03 to 1.19; p=0.01, per 1 log of ng/mL), HCC recurrence history pre-DAA initiation (RR=1.11, 95% CI 1.07 to 1.16; p<0.001), performance status (2 vs 0, RR=4.35, 95% CI 1.54 to 11.11; 2 vs 1, RR=3.7, 95% CI 1.3 to 11.11; p=0.01) and tumour burden pre-HCC treatment (multifocal vs solitary nodule, RR=1.75, 95% CI 1.25 to 2.43; p<0.001). No significant difference was observed in RR between the DAA-exposed and DAA-unexposed groups in propensity score-matched patients (RR=0.64, 95% CI 0.37 to 1.1; p=0.1). Conclusion Effects of DAA exposure on HCC recurrence risk remain inconclusive. Active clinical and radiological follow-up of patients with HCC after HCV eradication with DAA is justified.

Published
2022

70. Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment

Author

Pelizzaro, Filippo, Haxhi, Selion, Penzo, Barbara, Vitale, Alessandro, Giannini, Edoardo G, Sansone, Vito, Rapaccini, Gian Ludovico, Di Marco, Maria Teresa, Caturelli, Eugenio, Magalotti, Donatella, Sacco, Rodolfo, Celsa, Ciro, Campani, Claudia, Mega, Andrea, Guarino, Maria, Gasbarrini, Antonio, Svegliati-Baroni, Gianluca, Foschi, Francesco Giuseppe, Olivani, Andrea, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Azzaroli, Francesco, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Trevisani, Franco, Farinati, Fabio, Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X), Di Marco, Maria, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Pelizzaro, Filippo, Haxhi, Selion, Penzo, Barbara, Vitale, Alessandro, Giannini, Edoardo G, Sansone, Vito, Rapaccini, Gian Ludovico, Di Marco, Maria Teresa, Caturelli, Eugenio, Magalotti, Donatella, Sacco, Rodolfo, Celsa, Ciro, Campani, Claudia, Mega, Andrea, Guarino, Maria, Gasbarrini, Antonio, Svegliati-Baroni, Gianluca, Foschi, Francesco Giuseppe, Olivani, Andrea, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Azzaroli, Francesco, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Trevisani, Franco, Farinati, Fabio, Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X), Di Marco, Maria, and Gasbarrini, Antonio (ORCID:0000-0002-7278-4823)

Abstract

BackgroundTransarterial chemoembolization (TACE) is one of the most frequently applied treatments for hepatocellular carcinoma (HCC) worldwide. In this study, we aimed at evaluating whether and how TACE application and repetition, as well as the related outcome, have changed over the last three decades in Italy. MethodsData of 7,184 patients with HCC were retrieved from the Italian Liver Cancer (ITA.LI.CA) database. Patients were divided according to the period of diagnosis in six cohorts: P1 (1988-1993), P2 (1994-1998), P3 (1999-2004), P4 (2005-2009), P5 (2010-2014), and P6 (2015-2019). All the analyses were repeated in the overall patient population and in Barcelona Clinic Liver Cancer (BCLC) B patients, who are the subgroup of HCC patients originally supposed to receive TACE according to guidelines. TACE was defined as either the first or the main (more effective) treatment. ResultsThe proportion of patients receiving TACE as first or main therapy declined over time, and less than 50% of BCLC B patients were treated with chemoembolization from P3 onward. Conversely, TACE was widely used even outside the intermediate stage. Survival of TACE-treated patients progressively increased from P1 to P6. Although TACE was performed only once in the majority of patients, there was an increasing proportion of those receiving 2 or >= 3 treatments sessions over time. The overall survival (OS) of patients undergoing repeated treatments was significantly higher compared to those managed with a single TACE (median OS 40.0 vs. 65.0 vs. 71.8 months in 1, 2, and >= 3 TACE groups, respectively; p < 0.0001). However, after a first-line TACE, the adoption of curative therapies provided longer survival than repeating TACE (83.0 vs. 42.0 months; p < 0.0001), which in turn was associated with better outcomes compared to systemic therapies or best supportive care (BSC). ConclusionsDespite a decline in the percentage of treated patients over time, TACE has still an important rol

Published
2022

71. Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma: A Real-life Multicentric Weighted Comparison

Author

Famularo, Simone, Donadon, Matteo, Cipriani, Federica, Giuliante, Felice, Ferri, Silvia, Celsa, Ciro, Ferrero, Alessandro, Foschi, Francesco Giuseppe, Baiocchi, Gian Luca, Biasini, Elisabetta, Campani, Claudia, Valle, Raffaele Dalla, Pelizzaro, Filippo, Baroni, Gianluca Svegliati, Raimondo, Giovanni, Mega, Andrea, Chiarelli, Marco, Maestri, Marcello, Gasbarrini, Antonio, Jovine, Elio, Grazi, Gian Luca, Rapaccini, Gian Ludovico, Ruzzenente, Andrea, Morisco, Filomena, Sacco, Rodolfo, Memeo, Riccardo, Crespi, Michele, Antonucci, Adelmo, Bernasconi, Davide P, Romano, Fabrizio, Griseri, Guido, Aldrighetti, Luca, Torzilli, Guido, Trevisani, Franco, Giuliante, Felice (ORCID:0000-0001-9517-8220), Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X), Famularo, Simone, Donadon, Matteo, Cipriani, Federica, Giuliante, Felice, Ferri, Silvia, Celsa, Ciro, Ferrero, Alessandro, Foschi, Francesco Giuseppe, Baiocchi, Gian Luca, Biasini, Elisabetta, Campani, Claudia, Valle, Raffaele Dalla, Pelizzaro, Filippo, Baroni, Gianluca Svegliati, Raimondo, Giovanni, Mega, Andrea, Chiarelli, Marco, Maestri, Marcello, Gasbarrini, Antonio, Jovine, Elio, Grazi, Gian Luca, Rapaccini, Gian Ludovico, Ruzzenente, Andrea, Morisco, Filomena, Sacco, Rodolfo, Memeo, Riccardo, Crespi, Michele, Antonucci, Adelmo, Bernasconi, Davide P, Romano, Fabrizio, Griseri, Guido, Aldrighetti, Luca, Torzilli, Guido, Trevisani, Franco, Giuliante, Felice (ORCID:0000-0001-9517-8220), Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), and Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X)

Abstract

Objective: The aim of the study was to compare SURG vs SOR regarding the OS and progression-free survival (PFS) in a real-world clinical scenario. Background data: The treatment for advanced nonmetastatic HCC belonging to the Barcelona Clinic Liver Cancer stage C (BCLC C) is still controversial. Methods: BCLC C patients without extrahepatic spread and tumoral invasion of the main portal trunk were considered. Surgical patients were obtained from the HE.RC.O.LE.S. Register, whereas sorafenib patients were obtained from the ITA.LI.CA register The inverse probability weighting (IPW) method was adopted to balance the confounders between the 2 groups. Results: Between 2008 and 2019, 478 patients were enrolled: 303 in SURG and 175 in SOR group. Eastern Cooperative Oncological Group Performance Status (ECOG-PS), presence of cirrhosis, steatosis, Child-Pugh grade, hepatitis B virus and hepatitis C virus, alcohol intake, collateral veins, bilobar disease, localization of the tumor thrombus, number of nodules, alpha-fetoprotein, age, and Charlson Comorbidity index were weighted by IPW to create two balanced pseudo-populations: SURG = 374 and SOR = 263. After IPW, 1-3-5 years OS was 83.6%, 68.1%, 55.9% for SURG, and 42.3%, 17.8%, 12.8% for SOR (P < 0.001). Similar trends were observed after subgrouping patients by ECOG-PS = 0 and ECOG-PS >0, and by the intrahepatic location of portal vein invasion. At Cox regression, sorafenib treatment (hazard ratio 4.436; 95% confidence interval 3.19-6.15; P < 0.001) and Charlson Index (hazard ratio 1.162; 95% confidence interval 1.06-1.27; P = 0.010) were the only independent predictors of mortality. PFS at 1-3-5 years were 65.9%, 40.3%, 24.3% for SURG and 21.6%, 3.5%, 2.9% for SOR (P = 0.007). Conclusions: In BCLC C patients without extrahepatic spread but with intrahepatic portal invasion, liver resection, if feasible, was followed by better OS and PFS compared with sorafenib.

Published
2022

72. Hepatectomy Versus Sorafenib in Advanced Non-Metastatic Hepatocellular Carcinoma: A Real-Life Multicentric Weighted Comparison

Author

Famularo, S, Donadon, M, Cipriani, F, Giuliante, F, Ferri, S, Celsa, C, Ferrero, A, Foschi, F, Baiocchi, G, Biasini, E, Campani, C, Valle, R, Pellizzaro, F, Baroni, G, Raimondo, G, Mega, A, Chiarelli, M, Maestri, M, Gasbarrini, A, Jovine, E, Grazi, G, Rapaccini, G, Ruzzenente, A, Morisco, F, Sacco, R, Memeo, R, Crespi, M, Antonucci, A, Bernasconi, D, Romano, F, Griseri, G, Aldrighetti, L, Torzilli, G, Trevisani, F, Famularo, Simone, Donadon, Matteo, Cipriani, Federica, Giuliante, Felice, Ferri, Silvia, Celsa, Ciro, Ferrero, Alessandro, Foschi, Francesco Giuseppe, Baiocchi, Gian Luca, Biasini, Elisabetta, Campani, Claudia, Valle, Raffaele Dalla, Pellizzaro, Filippo, Baroni, Gianluca Svegliati, Raimondo, Giovanni, Mega, Andrea, Chiarelli, Marco, Maestri, Marcello, Gasbarrini, Antonio, Jovine, Elio, Grazi, Gian Luca, Rapaccini, Gian Ludovico, Ruzzenente, Andrea, Morisco, Filomena, Sacco, Rodolfo, Memeo, Riccardo, Crespi, Michele, Antonucci, Adelmo, Bernasconi, Davide P, Romano, Fabrizio, Griseri, Guido, Aldrighetti, Luca, Torzilli, Guido, Trevisani, Franco, Famularo, S, Donadon, M, Cipriani, F, Giuliante, F, Ferri, S, Celsa, C, Ferrero, A, Foschi, F, Baiocchi, G, Biasini, E, Campani, C, Valle, R, Pellizzaro, F, Baroni, G, Raimondo, G, Mega, A, Chiarelli, M, Maestri, M, Gasbarrini, A, Jovine, E, Grazi, G, Rapaccini, G, Ruzzenente, A, Morisco, F, Sacco, R, Memeo, R, Crespi, M, Antonucci, A, Bernasconi, D, Romano, F, Griseri, G, Aldrighetti, L, Torzilli, G, Trevisani, F, Famularo, Simone, Donadon, Matteo, Cipriani, Federica, Giuliante, Felice, Ferri, Silvia, Celsa, Ciro, Ferrero, Alessandro, Foschi, Francesco Giuseppe, Baiocchi, Gian Luca, Biasini, Elisabetta, Campani, Claudia, Valle, Raffaele Dalla, Pellizzaro, Filippo, Baroni, Gianluca Svegliati, Raimondo, Giovanni, Mega, Andrea, Chiarelli, Marco, Maestri, Marcello, Gasbarrini, Antonio, Jovine, Elio, Grazi, Gian Luca, Rapaccini, Gian Ludovico, Ruzzenente, Andrea, Morisco, Filomena, Sacco, Rodolfo, Memeo, Riccardo, Crespi, Michele, Antonucci, Adelmo, Bernasconi, Davide P, Romano, Fabrizio, Griseri, Guido, Aldrighetti, Luca, Torzilli, Guido, and Trevisani, Franco

Abstract

OBJECTIVE: The aim of the study was to compare SURG vs SOR regarding the OS and progression-free survival (PFS) in a real-world clinical scenario. BACKGROUND DATA: The treatment for advanced nonmetastatic HCC belonging to the Barcelona Clinic Liver Cancer stage C (BCLC C) is still controversial. METHODS: BCLC C patients without extrahepatic spread and tumoral invasion of the main portal trunk were considered. Surgical patients were obtained from the HE.RC.O.LE.S. Register, whereas sorafenib patients were obtained from the ITA.LI.CA register The inverse probability weighting (IPW) method was adopted to balance the confounders between the 2 groups. RESULTS: Between 2008 and 2019, 478 patients were enrolled: 303 in SURG and 175 in SOR group. Eastern Cooperative Oncological Group Performance Status (ECOG-PS), presence of cirrhosis, steatosis, Child-Pugh grade, hepatitis B virus and hepatitis C virus, alcohol intake, collateral veins, bilobar disease, localization of the tumor thrombus, number of nodules, alpha-fetoprotein, age, and Charlson Comorbidity index were weighted by IPW to create two balanced pseudo-populations: SURG = 374 and SOR = 263. After IPW, 1-3-5 years OS was 83.6%, 68.1%, 55.9% for SURG, and 42.3%, 17.8%, 12.8% for SOR (P [removed]0, and by the intrahepatic location of portal vein invasion. At Cox regression, sorafenib treatment (hazard ratio 4.436; 95% confidence interval 3.19-6.15; P < 0.001) and Charlson Index (hazard ratio 1.162; 95% confidence interval 1.06-1.27; P = 0.010) were the only independent predictors of mortality. PFS at 1-3-5 years were 65.9%, 40.3%, 24.3% for SURG and 21.6%, 3.5%, 2.9% for SOR (P = 0.007). CONCLUSIONS: In BCLC C patients without extrahepatic spread but with intrahepatic portal invasion, liver resection, if feasible, was followed by better OS and PFS compared with sorafenib.

Published
2022

73. Radiomics Analysis on Gadoxetate Disodium-Enhanced MRI Predicts Response to Transarterial Embolization in Patients with HCC

Author

Cannella, Roberto, primary, Cammà, Carla, additional, Matteini, Francesco, additional, Celsa, Ciro, additional, Giuffrida, Paolo, additional, Enea, Marco, additional, Comelli, Albert, additional, Stefano, Alessandro, additional, Cammà, Calogero, additional, Midiri, Massimo, additional, Lagalla, Roberto, additional, Brancatelli, Giuseppe, additional, and Vernuccio, Federica, additional

Published
2022
Full Text
View/download PDF

74. Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals

Author

Vernuccio, Federica, primary, Cannella, Roberto, additional, Cabibbo, Giuseppe, additional, Greco, Silvia, additional, Celsa, Ciro, additional, Matteini, Francesco, additional, Giuffrida, Paolo, additional, Midiri, Massimo, additional, Di Marco, Vito, additional, Cammà, Calogero, additional, and Brancatelli, Giuseppe, additional

Published
2022
Full Text
View/download PDF

75. Telemedicine Is an Effective Tool to Monitor Disease Activity in IBD Patients in the COVID-19 Era: A Single Centre Experience Based on Objective Data

Author

Sinagra, Emanuele, primary, Busacca, Anita, additional, Guida, Laura, additional, Carrozza, Lucio, additional, Brinch, Daniele, additional, Crispino, Federica, additional, Maida, Marcello, additional, Battaglia, Salvatore, additional, Celsa, Ciro, additional, Cammà, Calogero, additional, and Cappello, Maria, additional

Published
2022
Full Text
View/download PDF

76. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis

Author

Sapena, Victor, Enea, Marco, Torres, Ferran, Celsa, Ciro, Ríos, José J., Rizzo, Giacomo Emanuele Maria, Nahon, Pierre, Merchante Gutiérrez, Nicolás, Reig, Maria, and Universidad de Sevilla. Departamento de Medicina

Subjects
Meta-analysis, Hepatocellular carcinoma, Antiviral therapy, Individual patient
Abstract

Objective The benefit of direct-acting antivirals (DAAs) against HCV following successful treatment of hepatocellular carcinoma (HCC) remains controversial. This meta-analysis of individual patient data assessed HCC recurrence risk following DAA administration. Design We pooled the data of 977 consecutive patients from 21 studies of HCV-related cirrhosis and HCC, who achieved complete radiological response after surgical/locoregional treatments and received DAAs (DAA group). Recurrence or death risk was expressed as HCC recurrence or death per 100 person-years (100PY). Propensity score-matched patients from the ITA.LI.CA. cohort (n=328) served as DAA-unexposed controls (no-DAA group). Risk factors for HCC recurrence were identified using random-effects Poisson. Results Recurrence rate and death risk per 100PY in DAA-treated patients were 20 (95% CI 13.9 to 29.8, I2=74.6%) and 5.7 (2.5 to 15.3, I2=54.3), respectively. Predictive factors for recurrence were alpha-fetoprotein logarithm (relative risk (RR)=1.11, 95% CI 1.03 to 1.19; p=0.01, per 1 log of ng/mL), HCC recurrence history pre-DAA initiation (RR=1.11, 95% CI 1.07 to 1.16; p

Published
2022

77. Mortality after transjugular intrahepatic portosystemic shunt in older adult cirrhotic patients: a validated prediction model

Author

Vizzutti, Francesco, Celsa, Ciro, Calvaruso, Vincenza, Enea, Marco, Battaglia, Salvatore, Turco, Laura, Senzolo, Marco, Nardelli, Silvia, Miraglia, Roberto, Roccarina, Davide, Campani, Claudia, Saltini, Dario, Caporali, Cristian, Indulti, Federica, Gitto, Stefano, Zanetto, Alberto, Di Maria, Gabriele, Bianchini, Marcello, Pecchini, Maddalena, Aspite, Silvia, Di Bonaventura, Chiara, Citone, Michele, Guasconi, Tomas, Di Benedetto, Fabrizio, Arena, Umberto, Fanelli, Fabrizio, Maruzzelli, Luigi, Riggio, Oliviero, Burra, Patrizia, Colecchia, Antonio, Villa, Erica, Marra, Fabio, Cammà, Calogero, and Schepis, Filippo

Published
2022

78. Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment

Author

Pelizzaro, Filippo, primary, Haxhi, Selion, additional, Penzo, Barbara, additional, Vitale, Alessandro, additional, Giannini, Edoardo G., additional, Sansone, Vito, additional, Rapaccini, Gian Ludovico, additional, Di Marco, Maria, additional, Caturelli, Eugenio, additional, Magalotti, Donatella, additional, Sacco, Rodolfo, additional, Celsa, Ciro, additional, Campani, Claudia, additional, Mega, Andrea, additional, Guarino, Maria, additional, Gasbarrini, Antonio, additional, Svegliati-Baroni, Gianluca, additional, Foschi, Francesco Giuseppe, additional, Olivani, Andrea, additional, Masotto, Alberto, additional, Nardone, Gerardo, additional, Raimondo, Giovanni, additional, Azzaroli, Francesco, additional, Vidili, Gianpaolo, additional, Brunetto, Maurizia Rossana, additional, Trevisani, Franco, additional, and Farinati, Fabio, additional

Published
2022
Full Text
View/download PDF

80. Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy

Author

Burgio, Valentina, primary, Iavarone, Massimo, additional, Di Costanzo, Giovan Giuseppe, additional, Marra, Fabio, additional, Lonardi, Sara, additional, Tamburini, Emiliano, additional, Piscaglia, Fabio, additional, Masi, Gianluca, additional, Celsa, Ciro, additional, Foschi, Francesco Giuseppe, additional, Silletta, Marianna, additional, Amoruso, Daniela Caterina, additional, Rimini, Margherita, additional, Bruccoleri, Mariangela, additional, Tortora, Raffaella, additional, Campani, Claudia, additional, Soldà, Caterina, additional, Viola, Massimo Giuseppe, additional, Forgione, Antonella, additional, Conti, Fabio, additional, Salani, Francesca, additional, Catanese, Silvia, additional, Giacchetto, Carmelo Marco, additional, Fulgenzi, Claudia Angela Maria, additional, Coppola, Carmine, additional, Lampertico, Pietro, additional, Pellino, Antonio, additional, Rancatore, Gabriele, additional, Cabibbo, Giuseppe, additional, Ratti, Francesca, additional, Pedica, Federica, additional, Della Corte, Angelo, additional, Colombo, Massimo, additional, De Cobelli, Francesco, additional, Aldrighetti, Luca, additional, Cascinu, Stefano, additional, and Casadei-Gardini, Andrea, additional

Published
2021
Full Text
View/download PDF

81. Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction model.

Author

Vizzutti, Francesco, Celsa, Ciro, Calvaruso, Vincenza, Enea, Marco, Battaglia, Salvatore, Turco, Laura, Senzolo, Marco, Nardelli, Silvia, Miraglia, Roberto, Roccarina, Davide, Campani, Claudia, Saltini, Dario, Caporali, Cristian, Indulti, Federica, Gitto, Stefano, Zanetto, Alberto, Di Maria, Gabriele, Bianchini, Marcello, Pecchini, Maddalena, and Aspite, Silvia

Published
2023
Full Text
View/download PDF

82. First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials

Author

Cabibbo, Giuseppe, primary, Reig, Maria, additional, Celsa, Ciro, additional, Torres, Ferran, additional, Battaglia, Salvatore, additional, Enea, Marco, additional, Rizzo, Giacomo Emanuele Maria, additional, Petta, Salvatore, additional, Calvaruso, Vincenza, additional, Di Marco, Vito, additional, Craxì, Antonio, additional, Singal, Amit G., additional, Bruix, Jordi, additional, and Cammà, Calogero, additional

Published
2021
Full Text
View/download PDF

84. Surveillance as determinant of long-term survival in non-transplanted hepatocellular carcinoma patients

Author

Pelizzaro, Filippo, Vitale, Alessandro, Sartori, Anna, Vieno, Andrea, Penzo, Barbara, Russo, Francesco, Frigo, Anna, Giannini, Edoardo, Piccinnu, Manuela, Rapaccini, Gian, Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Sacco, Rodolfo, Celsa, Ciro, Marra, Fabio, Mega, Andrea, Guarino, Maria, Gasbarrini, Antonio, Svegliati-Baroni, Gianluca, Foschi, Francesco, Olivani, Andrea, Masotto, Alberto, Coccoli, Pietro, Raimondo, Giovanni, Azzaroli, Francesco, Vidili, Gianpaolo, Brunetto, Maurizia, Trevisani, Franco, Farinati, Fabio, Group, on behalf of ITA.LI.CA study, Pelizzaro F., Vitale A., Sartori A., Vieno A., Penzo B., Russo F.P., Frigo A.C., Giannini E.G., Piccinnu M., Rapaccini G.L., Di Marco M., Caturelli E., Zoli M., Sacco R., Celsa C., Marra F., Mega A., Guarino M., Gasbarrini A., Svegliati-Baroni G., Foschi F.G., Olivani A., Masotto A., Coccoli P., Raimondo G., Azzaroli F., Vidili G., Brunetto M.R., Trevisani F., and Farinati F.

Subjects
Cancer Research, medicine.medical_specialty, Hepatocellular carcinoma, Settore MED/12 - GASTROENTEROLOGIA, Cancer stage, Independent predictor, Logistic regression, lcsh:RC254-282, Article, 03 medical and health sciences, Long-term survival, 0302 clinical medicine, Internal medicine, Long term survival, medicine, Treatment, Surveillance, business.industry, Settore MED/09 - MEDICINA INTERNA, Confounding, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Oncology, 030220 oncology & carcinogenesis, Baseline characteristics, 030211 gastroenterology & hepatology, business
Abstract

Purpose: We aimed at assessing the impact of surveillance on long-term survival in HCC patients. Methods: From the ITA.LI.CA database, we selected 1028 cases with long (≥5 years, LS group) and 2721 controls with short-term survival (&lt, 5 years, SS group). The association between surveillance and LS was adjusted for confounders by multivariable logistic regression analysis. Survival of surveilled patients was presented both as observed and corrected for the lead-time bias, and the comparison of survival between surveillance and no surveillance groups was also performed after balancing the baseline characteristics with inverse probability weights (IPW). Results: LS patients were more frequently diagnosed under surveillance (p &lt, 0.0001), and had more favorable baseline characteristics. Surveillance was an independent predictor of LS (OR = 1.413, 95% CI 1.195–1.671, p &lt, 0.0001). The observed and the lead-time corrected survival of surveilled patients were significantly longer compared to the survival of not surveilled patients (p &lt, 0.0001 and p = 0.0008, respectively). In IPW adjusted populations, no survival differences were demonstrated between the two groups (p = 0.30). Conclusions: Surveillance, increasing early-stage diagnosis and applicability of curative treatments, is a fundamental determinant of long-term survival in HCC patients. A wide implementation of surveillance programs should be pursued in order to improve HCC patients’ prognosis.

Published
2021

85. First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials

Author

Cabibbo, Giuseppe, Reig, Maria, Celsa, Ciro, Torres, Ferran, Battaglia, Salvatore, Enea, Marco, Rizzo, Giacomo Emanuele Maria, Petta, Salvatore, Calvaruso, Vincenza, Di Marco, Vito, Craxì, Antonio, Singal, Amit G., Bruix, Jordi, and Cammà, Calogero

Abstract

Introduction:Atezolizumab (ATEZO) plus bevacizumab (BEVA) represents the new standard of care for the treatment of advanced hepatocellular carcinoma (HCC). However, the choice of the second-line treatment after the failure of immunotherapy-based first-line remains elusive. Taking into account the weaknesses of the available evidence, we developed a simulation model based on available phase III randomized clinical trials (RCTs) to identify optimal risk/benefit sequential strategies. Methods:A Markov model was built to estimate the overall survival (OS) of sequential first- and second-line systemic treatments. Sequences starting with first-line ATEZO plus BEVA followed by 5 second-line treatments (sorafenib [SORA], lenvatinib [LENVA], regorafenib, cabozantinib, and ramucirumab) were compared. The probability of transition between states (initial treatment, cancer progression, and death) was derived from RCTs. Life-year gained (LYG) was the main outcome. Rates of severe adverse events (SAEs) (≥ grade 3) were calculated. The incremental safety-effectiveness ratio (ISER) was calculated as the difference in probability of SAEs divided by LYG between the 2 most effective sequences. Results:ATEZO plus BEVA followed by LENVA (median OS, 24 months) or SORA (median OS, 23 months) was the most effective sequence, producing a LYG of 0.50 and 0.42 year, respectively. ATEZO plus BEVA followed by SORA was the safest sequence (SAEs 63%). At a willingness-to-risk threshold of 10% of SAEs for LYG, ATEZO plus BEVA followed by second-line SORA was favored in 72% of cases, while at a threshold of 30% of SAEs for LYG, ATEZO plus BEVA followed by second-line LENVA was favored in 69% of cases. Conclusion:Our simulation model provides a strong rationale to support ongoing trials evaluating second-line tyrosine-kinase inhibitors after first-line ATEZO plus BEVA. Future evidence from ongoing RCTs and prospective real-world studies are needed to prove the net health benefit of sequential treatment options for advanced HCC.

Published
2023
Full Text
View/download PDF

86. Long‐term evolution of LI‐RADS observations in HCV‐related cirrhosis treated with direct‐acting antivirals

Author

Cannella, Roberto, primary, Vernuccio, Federica, additional, Celsa, Ciro, additional, Cabibbo, Giuseppe, additional, Calvaruso, Vincenza, additional, Greco, Silvia, additional, Battaglia, Salvatore, additional, Choudhury, Kingshuk Roy, additional, Tang, An, additional, Midiri, Massimo, additional, Di Marco, Vito, additional, Cammà, Calogero, additional, and Brancatelli, Giuseppe, additional

Published
2021
Full Text
View/download PDF

87. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis

Author

Sapena, Victor, primary, Enea, Marco, additional, Torres, Ferran, additional, Celsa, Ciro, additional, Rios, Jose, additional, Rizzo, Giacomo Emanuele Maria, additional, Nahon, Pierre, additional, Mariño, Zoe, additional, Tateishi, Ryosuke, additional, Minami, Tatsuya, additional, Sangiovanni, Angelo, additional, Forns, Xavier, additional, Toyoda, Hidenori, additional, Brillanti, Stefano, additional, Conti, Fabio, additional, Degasperi, Elisabetta, additional, Yu, Ming-Lung, additional, Tsai, Pei-Chien, additional, Jean, Kevin, additional, El Kassas, Mohamed, additional, Shousha, Hend Ibrahim, additional, Omar, Ashraf, additional, Zavaglia, Claudio, additional, Nagata, Hiroko, additional, Nakagawa, Mina, additional, Asahina, Yasuhiro, additional, Singal, Amit G, additional, Murphy, Caitlin, additional, Kohla, Mohamed, additional, Masetti, Chiara, additional, Dufour, Jean-François, additional, Merchante, Nicolas, additional, Cavalletto, Luisa, additional, chemello, liliana LC, additional, POL, Stanislas, additional, Crespo, Javier, additional, Calleja, Jose Luis, additional, Villani, Rosanna, additional, Serviddio, Gaetano, additional, Zanetto, Alberto, additional, Shalaby, Sarah, additional, Russo, Francesco Paolo, additional, Bielen, Rob, additional, Trevisani, Franco, additional, Cammà, Calogero, additional, Bruix, Jordi, additional, Cabibbo, Giuseppe, additional, and Reig, Maria, additional

Published
2021
Full Text
View/download PDF

88. Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization?

Author

Celsa, Ciro, primary, Cabibbo, Giuseppe, additional, Enea, Marco, additional, Battaglia, Salvatore, additional, Rizzo, Giacomo E. M., additional, Busacca, Anita, additional, Giuffrida, Paolo, additional, Stornello, Caterina, additional, Brancatelli, Giuseppe, additional, Cannella, Roberto, additional, Gruttadauria, Salvatore, additional, and Cammà, Calogero, additional

Published
2021
Full Text
View/download PDF

89. Focal liver lesion: clinical indication for biopsy after radiological workup

Author

Gozzo, Cecilia, Celsa, Ciro, Cabibbo, Giuseppe, Maruzzelli, Luigi, Miraglia, Roberto, and Bartolotta Tommaso, Vincenzo.

Subjects
Liver, Biopsy, Retrospective, Ultrasound, Interventional Radiology, Performed at one institution, Tissue characterisation, Interventional non-vascular, Liver - Focal Liver Lesions, Observational
Abstract

Purpose Methods and materials Results Conclusion Personal information and conflict of interest References, Purpose: To investigate the clinical indication for US-guided biopsy of focal liver lesion based on radiology...

Published
2020
Full Text
View/download PDF

91. THU-144 - Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis

Author

Celsa, Ciro, Cabibbo, Giuseppe, Di Maria, Gabriele, Vaccaro, Marco, Battaglia, Salvatore, Maria Rizzo, Giacomo Emanuele, Ciccia, Roberta, Grova, Alessandro, Salvato, Mauro, Giuffrida, Paolo, Giacchetto, Marco, Rancatore, Gabriele, Grassini, Maria Vittoria, Antonucci, Michela, Morana, Piera, Enea, Marco, and Camma, Calogero

Published
2023
Full Text
View/download PDF

92. WED-260 - RESIST criteria accurately rule-out high-risk esophageal varices in patients with primary biliary cholangitis and compensated advanced chronic liver disease

Author

Calvaruso, Vincenza, Celsa, Ciro, Cristoferi, Laura, Scaravaglio, Miki, Capodicasa, Luigi, Cadamuro, Luca, Di Maria, Gabriele, Di Marco, Vito, Gerussi, Alessio, Malinverno, Federica, Lampertico, Pietro, Cazzagon, Nora, Marzioni, Marco, Gentilucci, Umberto Vespasiani, Andreone, Pietro, Lleo, Ana, Rigamonti, Cristina, Giannini, Edoardo Giovanni, Russello, Maurizio, Vanni, Ester, Cerini, Federica, Missale, Gabriele, Brunetto, Maurizia, Niro, Grazia, Vettori, Giovanni, Castellaneta, Antonino, Alvaro, Domenico, Palitti, Valeria Pace, Bellanti, Francesco, Invernizzi, Pietro, Camma, Calogero, and Carbone, Marco

Published
2023
Full Text
View/download PDF

94. Identification of Clinical Phenotypes and Related Survival in Patients with Large HCCs

Author

Carr, Brian I., primary, Guerra, Vito, additional, Donghia, Rossella, additional, Farinati, Fabio, additional, Giannini, Edoardo G., additional, Muratori, Luca, additional, Rapaccini, Gian Ludovico, additional, Di Marco, Maria, additional, Caturelli, Eugenio, additional, Zoli, Marco, additional, Sacco, Rodolfo, additional, Celsa, Ciro, additional, Campani, Claudia, additional, Mega, Andrea, additional, Guarino, Maria, additional, Gasbarrini, Antonio, additional, Svegliati-Baroni, Gianluca, additional, Foschi, Francesco Giuseppe, additional, Biasini, Elisabetta, additional, Masotto, Alberto, additional, Nardone, Gerardo, additional, Raimondo, Giovanni, additional, Azzaroli, Francesco, additional, Vidili, Gianpaolo, additional, Brunetto, Maurizia Rossana, additional, and Trevisani, Franco, additional

Published
2021
Full Text
View/download PDF

97. Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use

Author

Magro, Bianca, primary, Zuccaro, Valentina, additional, Novelli, Luca, additional, Zileri, Lorenzo, additional, Celsa, Ciro, additional, Raimondi, Federico, additional, Gori, Mauro, additional, Cammà, Giulia, additional, Battaglia, Salvatore, additional, Genova, Vincenzo Giuseppe, additional, Paris, Laura, additional, Tacelli, Matteo, additional, Mancarella, Francesco Antonio, additional, Enea, Marco, additional, Attanasio, Massimo, additional, Senni, Michele, additional, Di Marco, Fabiano, additional, Lorini, Luca Ferdinando, additional, Fagiuoli, Stefano, additional, Bruno, Raffaele, additional, Cammà, Calogero, additional, and Gasbarrini, Antonio, additional

Published
2021
Full Text
View/download PDF

98. Impact of biliary stents on the diagnostic accuracy of EUS-guided fine-needle biopsy of solid pancreatic head lesions: A multicenter study

Author

Crinò, StefanoFrancesco, primary, Conti Bellocchi, MariaCristina, additional, Antonini, Filippo, additional, Macarri, Giampiero, additional, Carrara, Silvia, additional, Lamonaca, Laura, additional, Di Mitri, Roberto, additional, Conte, Elisabetta, additional, Fabbri, Carlo, additional, Binda, Cecilia, additional, Ofosu, Andrew, additional, Gasparini, Enrico, additional, Turri, Chiara, additional, Stornello, Caterina, additional, Celsa, Ciro, additional, Larghi, Alberto, additional, Manfrin, Erminia, additional, Gabbrielli, Armando, additional, Facciorusso, Antonio, additional, and Tacelli, Matteo, additional

Published
2021
Full Text
View/download PDF

99. Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma

Author

Cabibbo, Giuseppe, primary, Celsa, Ciro, additional, Enea, Marco, additional, Battaglia, Salvatore, additional, Rizzo, Giacomo Emanuele Maria, additional, Busacca, Anita, additional, Matranga, Domenica, additional, Attanasio, Massimo, additional, Reig, Maria, additional, Craxì, Antonio, additional, and Cammà, Calogero, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results